Compile Data Set for Download or QSAR
Report error Found 306 Enz. Inhib. hit(s) with all data for entry = 2684
TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375641(US9908897, Example 21)
Affinity DataIC50: 0.776nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375697(US9908897, Example 75)
Affinity DataIC50: 1.32nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375651(US9908897, Example 37)
Affinity DataIC50: 1.38nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375716(US9908897, Example 92)
Affinity DataIC50: 1.45nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375686(US9908897, Example 65)
Affinity DataIC50: 1.62nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375717(US9908897, Example 93 | US9908897, Example 94)
Affinity DataIC50: 2.04nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375709(US9908897, Example 87)
Affinity DataIC50: 2.14nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375644(US9908897, Example 25)
Affinity DataIC50: 2.19nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375640(US9908897, Example 19)
Affinity DataIC50: 2.29nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375652(US9908897, Example 38)
Affinity DataIC50: 2.45nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375722(US9908897, Example 98)
Affinity DataIC50: 2.57nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375649(US9908897, Example 35)
Affinity DataIC50: 3.55nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375717(US9908897, Example 93 | US9908897, Example 94)
Affinity DataIC50: 3.63nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375639(US9908897, Example 17)
Affinity DataIC50: 3.80nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375675(US9908897, Example 56)
Affinity DataIC50: 3.80nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375720(US9908897, Example 96 | US9908897, Example 97)
Affinity DataIC50: 3.89nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50: 4.17nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375636(US9908897, Example 13)
Affinity DataIC50: 4.17nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375696(US9908897, Example 74)
Affinity DataIC50: 4.17nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375714(US9908897, Example 90)
Affinity DataIC50: 4.37nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375642(US9908897, Example 23)
Affinity DataIC50: 4.79nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375660(US9908897, Example 44)
Affinity DataIC50: 5.13nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375687(US9908897, Example 66)
Affinity DataIC50: 5.13nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50: 5.62nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375669(US9908897, Example 50)
Affinity DataIC50: 5.75nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375674(US9908897, Example 55)
Affinity DataIC50: 6.46nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375649(US9908897, Example 35)
Affinity DataIC50: 6.92nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375719(US9908897, Example 95)
Affinity DataIC50: 6.92nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375710(US9908897, Example 88)
Affinity DataIC50: 7.08nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 7.24nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375704(US9908897, Example 82)
Affinity DataIC50: 7.24nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375699(US9908897, Example 77)
Affinity DataIC50: 8.32nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375684(US9908897, Example 63)
Affinity DataIC50: 8.51nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375662(US9908897, Example 46)
Affinity DataIC50: 9.33nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375659(US9908897, Example 43)
Affinity DataIC50: 9.77nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375680(US9908897, Example 59)
Affinity DataIC50: 9.77nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375683(US9908897, Example 62)
Affinity DataIC50: 9.77nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375715(US9908897, Example 91)
Affinity DataIC50: 9.77nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375704(US9908897, Example 82)
Affinity DataIC50: 10nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375723(US9908897, Example 102)
Affinity DataIC50: 10nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 11nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375720(US9908897, Example 96 | US9908897, Example 97)
Affinity DataIC50: 11.2nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375700(US9908897, Example 78)
Affinity DataIC50: 11.5nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375706(US9908897, Example 84)
Affinity DataIC50: 11.5nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375676(US9908897, Example 57)
Affinity DataIC50: 12.9nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375701(US9908897, Example 79)
Affinity DataIC50: 13.8nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375688(US9908897, Example 67)
Affinity DataIC50: 15.8nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375713(US9908897, Example 89)
Affinity DataIC50: 18.6nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375627(US9908897, Example 5)
Affinity DataIC50: 23.4nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375661(US9908897, Example 45)
Affinity DataIC50: 25.7nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 306 total ) | Next | Last >>
Jump to: